The immune system protects our body against foreign invaders. When
cancer develops, the immune system (partly) fails to eliminate tumour cells.
Active cancer immunotherapy attempts to activate the patient’s own immune
system to attack the cancer cells. Dendritic cells are most powerful initiators
of immune responses.
MesoPher® consists of autologous dendritic cells loaded with
allogeneic tumour cell lysate.
Blood from patients is collected and dendritic cells are cultured ex
vivo (=outside the body). The autologous (=from the patient) dendritic
cells are instructed with a lysate made of a number of mesothelioma tumour cell
lines (allogeneic lysate). The patient is then treated with her/his own
activated dendritic cells.